Novo Ventures and HBM Partners have led a CHF 100m series-C funding round for Switzerland-based Numab Therapeutics, a multi-specific antibodies developer.
B2B growth technology investor held a first close for the fund in 2020, raising more than EUR 100m
Family office ATHOS is co-investing in the deal, which sees the Swiss drug autoinjector group exit EQT VIII
Houlihan Lokey will advise on auction for the Italian Italian bicycle manufacturer
Head of private equity Christophe de Dardel takes up the role after 22 years with the Swiss asset manager